CN109970794B - S-取代-3-吲哚硫磷酸酯类衍生物及制备方法和应用 - Google Patents
S-取代-3-吲哚硫磷酸酯类衍生物及制备方法和应用 Download PDFInfo
- Publication number
- CN109970794B CN109970794B CN201910205589.1A CN201910205589A CN109970794B CN 109970794 B CN109970794 B CN 109970794B CN 201910205589 A CN201910205589 A CN 201910205589A CN 109970794 B CN109970794 B CN 109970794B
- Authority
- CN
- China
- Prior art keywords
- indole
- substituted
- cdcl
- ppm
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 21
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 18
- 239000002994 raw material Substances 0.000 abstract description 17
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 10
- 238000003756 stirring Methods 0.000 abstract description 10
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 7
- 150000002475 indoles Chemical class 0.000 abstract description 7
- 239000002904 solvent Substances 0.000 abstract description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 4
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract description 3
- 239000007800 oxidant agent Substances 0.000 abstract description 3
- 230000001590 oxidative effect Effects 0.000 abstract description 3
- 150000002978 peroxides Chemical class 0.000 abstract description 3
- QCJQWJKKTGJDCM-UHFFFAOYSA-N [P].[S] Chemical compound [P].[S] QCJQWJKKTGJDCM-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003054 catalyst Substances 0.000 abstract description 2
- GBHRVZIGDIUCJB-UHFFFAOYSA-N hydrogenphosphite Chemical compound OP([O-])[O-] GBHRVZIGDIUCJB-UHFFFAOYSA-N 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 238000010992 reflux Methods 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 132
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 238000000034 method Methods 0.000 description 27
- 238000004679 31P NMR spectroscopy Methods 0.000 description 24
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- 239000011734 sodium Substances 0.000 description 22
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 235000009518 sodium iodide Nutrition 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- -1 t-butanol peroxide Chemical class 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- PKUWKAXTAVNIJR-UHFFFAOYSA-M O,O-diethyl thiophosphate Chemical compound CCOP([O-])(=S)OCC PKUWKAXTAVNIJR-UHFFFAOYSA-M 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ADZUEEUKBYCSEY-UHFFFAOYSA-N 1h-indole-5-carbaldehyde Chemical compound O=CC1=CC=C2NC=CC2=C1 ADZUEEUKBYCSEY-UHFFFAOYSA-N 0.000 description 2
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical compound C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 2
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 2
- 239000005949 Malathion Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229960002133 almotriptan Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 2
- SULWMEGSVQCTSK-UHFFFAOYSA-N diethyl hydrogen phosphite Chemical compound CCOP(O)OCC SULWMEGSVQCTSK-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930005303 indole alkaloid Natural products 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 229960000453 malathion Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- AMKVXSZCKVJAGH-UHFFFAOYSA-N naratriptan Chemical compound C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AMKVXSZCKVJAGH-UHFFFAOYSA-N 0.000 description 2
- 229960005254 naratriptan Drugs 0.000 description 2
- PZXOQEXFMJCDPG-UHFFFAOYSA-N omethoate Chemical compound CNC(=O)CSP(=O)(OC)OC PZXOQEXFMJCDPG-UHFFFAOYSA-N 0.000 description 2
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 2
- 229960000425 rizatriptan Drugs 0.000 description 2
- ULFRLSNUDGIQQP-UHFFFAOYSA-N rizatriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CN1C=NC=N1 ULFRLSNUDGIQQP-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N tert-butyl alcohol Substances CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 1
- UHQAIJFIXCOBCN-UHFFFAOYSA-N 1-methylindole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(C)C=CC2=C1 UHQAIJFIXCOBCN-UHFFFAOYSA-N 0.000 description 1
- YBFCBQMICVOSRW-UHFFFAOYSA-N 1-phenylindole Chemical compound C1=CC2=CC=CC=C2N1C1=CC=CC=C1 YBFCBQMICVOSRW-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical compound N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 description 1
- KDHWCFCNNGUJCP-UHFFFAOYSA-N 2-phenylimidazo[1,2-a]pyridine Chemical compound N1=C2C=CC=CN2C=C1C1=CC=CC=C1 KDHWCFCNNGUJCP-UHFFFAOYSA-N 0.000 description 1
- HJENUMMIFDMCEN-UHFFFAOYSA-N 2-propyl-1h-indole Chemical compound C1=CC=C2NC(CCC)=CC2=C1 HJENUMMIFDMCEN-UHFFFAOYSA-N 0.000 description 1
- VYXXECBUSAHQQR-UHFFFAOYSA-N 4-phenoxy-1h-indole Chemical compound C=1C=CC=2NC=CC=2C=1OC1=CC=CC=C1 VYXXECBUSAHQQR-UHFFFAOYSA-N 0.000 description 1
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 1
- MYTGFBZJLDLWQG-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2NC=CC2=C1 MYTGFBZJLDLWQG-UHFFFAOYSA-N 0.000 description 1
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
- TVQLYTUWUQMGMP-UHFFFAOYSA-N 5-iodo-1h-indole Chemical compound IC1=CC=C2NC=CC2=C1 TVQLYTUWUQMGMP-UHFFFAOYSA-N 0.000 description 1
- DWAQDRSOVMLGRQ-UHFFFAOYSA-N 5-methoxyindole Chemical compound COC1=CC=C2NC=CC2=C1 DWAQDRSOVMLGRQ-UHFFFAOYSA-N 0.000 description 1
- KGWPHCDTOLQQEP-UHFFFAOYSA-N 7-methylindole Chemical compound CC1=CC=CC2=C1NC=C2 KGWPHCDTOLQQEP-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- FAXIJTUDSBIMHY-UHFFFAOYSA-N diethoxy-(2-ethylsulfanylethoxy)-sulfanylidene-$l^{5}-phosphane;1-diethoxyphosphorylsulfanyl-2-ethylsulfanylethane Chemical compound CCOP(=O)(OCC)SCCSCC.CCOP(=S)(OCC)OCCSCC FAXIJTUDSBIMHY-UHFFFAOYSA-N 0.000 description 1
- XFMJUIKWKVJNDY-UHFFFAOYSA-N diethoxyphosphorylsulfanylmethylbenzene Chemical compound CCOP(=O)(OCC)SCC1=CC=CC=C1 XFMJUIKWKVJNDY-UHFFFAOYSA-N 0.000 description 1
- CZHYKKAKFWLGJO-UHFFFAOYSA-N dimethyl phosphite Chemical compound COP([O-])OC CZHYKKAKFWLGJO-UHFFFAOYSA-N 0.000 description 1
- NFORZJQPTUSMRL-UHFFFAOYSA-N dipropan-2-yl hydrogen phosphite Chemical compound CC(C)OP(O)OC(C)C NFORZJQPTUSMRL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
- 229960002284 frovatriptan Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- DRYBMFJLYYEOBZ-UHFFFAOYSA-N methyl 1h-indole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC=CC2=C1 DRYBMFJLYYEOBZ-UHFFFAOYSA-N 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
S‑取代‑3‑吲哚硫磷酸酯类衍生物及制备方法和应用，涉及吲哚类药物。以吲哚衍生物、硫粉和氢亚磷酸酯为原料，碘化物为催化剂，加入溶剂，在搅拌状态下加入过氧化物类氧化剂，升温加热至回流，即得S‑取代‑3‑吲哚硫磷酸酯类衍生物。S‑取代‑3‑吲哚硫磷酸酯类衍生物及药物组合物可在制备诊断和治疗炎症性药物的应用。将吲哚模块和有机硫磷模块共同构建在同一分子内，这类化合物表现了一定的抗炎活性。所述S‑取代‑3‑吲哚硫磷酸酯类衍生物的结构上具有较高的创造性。同时，S‑取代‑3‑吲哚硫磷酸酯类衍生物的制备方法反应成本低，产率高，反应过程简单易控制，适用于工业化生产。
Description
技术领域
本发明涉及吲哚类药物，尤其是涉S-取代-3-吲哚硫磷酸酯类衍生物及其制备方法和应用。
背景技术
吲哚类药物广泛用于炎症的治疗，同时，吲哚衍生物具有丰富的生物活性，所以近百年来，研究构建新型的吲哚衍生物并研究其新的生物活性成为药学家和合成化学家的重点课题。生命体中的色氨酸也是吲哚的衍生物；吲哚类生物碱具有很好的生理活性([1]Shiri,M.Chem.Rev.2012,112,3508；[2]Walker,S.R.；Carter,E.J.；Huff,B.C.；Morris,J.C.Chem.Rev.2009,109,3080；[3]Chadha,N.；Silakari,O.Eur.J.Med.Chem.2017,134,159)，目前，已有很多吲哚类生物碱开发成为药物，代表药物主要有那拉曲坦(Naratriptan)、吲哚美辛(Indomethacin)、阿莫曲坦(Almotriptan)、利扎曲普坦(Rizatriptan)、佐米曲普坦(Zolmitriptan)、夫罗曲坦(Frovatriptan)、阿西美辛(Acemetacin)等。
另一方面，硫磷酸酯是比较常见的一种有机磷化合物，在药物合成、农药以及有机合成等众多领域有着十分广泛的应用，其结构都非常简单，但具有很强的生物活性([4]Azran,S.；Danino,O.；
D.；Kenigsberg,S.；Reiser,G.；Dixit,M.；Singh,V.；Major,D.T.；Fischer,B.J.Med.Chem.2015,58,8427；[5]Shivalingam,A.；Tyburn,A.E.S.；El-Sagheer,A.H.；Brown,T.J.Am.Chem.Soc.2017,139,1575.)，如比较常见的对硫磷(Parathion)、碘硫磷(Iodofenphos)、內吸磷(Demeton)、马拉硫磷(Malathion)、氧乐果(Omethoate)、稻瘟净(Kitazin)等。
发明内容
本发明的第一目的在于提供具有新结构的一类S-取代-3-吲哚硫磷酸酯类衍生物及其制备方法。
本发明的第二目的在于提供一类S-取代-3-吲哚硫磷酸酯类衍生物及药物组合物在制备诊断和治疗炎症性药物的应用。
所述S-取代-3-吲哚硫磷酸酯类衍生物的通式如下：
其中，R1代表H或烷基或各类芳香基团或胺类或羧酸衍生物或烷氧基或卤素等，优选为H、Cl、F、烷氧基、羧酸酯、酰胺；R2代表H或烷基或各类芳香基团，优选为H或甲基或苯基；R3代表烷基或各类芳香基团，优选C1～C4的直链烷基、C5或C6的环烷基、金刚烷基、取代或未取代的芳香烷基、取代或未取代的苄基、取代或未取代的杂环化合物，最好为甲基、乙基、异丙基。
所述S-取代-3-吲哚硫磷酸酯类衍生物的制备方法的具体步骤如下：
以吲哚衍生物、硫粉和氢亚磷酸酯为原料，碘化物为催化剂，加入溶剂，在搅拌状态下加入过氧化物类氧化剂，升温加热至回流，即得S-取代-3-吲哚硫磷酸酯类衍生物。
所述碘化物可选自碘化钠、碘化钾、四丁基碘化铵等中的一种；所述溶剂可选自乙腈、乙醇、水等中的一种；所述过氧化物类氧化剂可选自过氧化叔丁醇、双氧水等中的一种。
所述S-取代-3-吲哚硫磷酸酯类衍生物的合成路线为：
所述S-取代-3-吲哚硫磷酸酯类衍生物及药物组合物可在制备诊断和治疗炎症性药物的应用。所述炎症可包括胃炎、肺炎等。
本发明将吲哚模块和有机硫磷模块共同构建在同一分子内，这类化合物表现了一定的抗炎活性。所述S-取代-3-吲哚硫磷酸酯类衍生物的结构上具有较高的创造性。同时，S-取代-3-吲哚硫磷酸酯类衍生物的制备方法反应成本低，产率高，反应过程简单易控制，适用于工业化生产。
附图说明
图1为本发明实施例部分化合物的细胞毒性(20μmol/L)
具体实施方式
为了便于理解本发明，现结合具体实施方式对本发明作进一步说明。
为了清楚说明本发明，实施例中所描述的化合物结构和编号列在以下的表格中。
方法一：实施例1：S-取代-3-吲哚硫磷酸二乙酯的制备(化合物7)
在250mL反应瓶中依次加入硫粉(3.84g,0.12mol)，氢亚磷酸二乙酯(13.80g,0.10mol)，三乙胺(10.10g,0.10mol)，二氯甲烷(100mL)，室温搅拌10h，TLC检测反应已结束，停止反应。反应液加入盐酸水溶液洗涤，有机相减压浓缩得浅黄色液体硫代磷酸二乙酯17.0g，收率100％，31PNMR：58ppm。
在150mL反应瓶中，先依次加入吲哚(1.17g,10mmol)，硫代磷酸二乙酯(2.55g,15mmol)，碘化钠(0.15g,1mmol)，加入乙醇20mL,再在搅拌状态下加入过氧化叔丁醇(70％浓度，2.6g,20mmol)，60℃保温反应8h。TLC检测反应已结束，停止反应。反应液冷却至室温，在搅拌下加入80mL乙酸乙酯，并用碳酸氢钠调pH为7～8；液体过滤后分液，有机相用15g无水硫酸钠干燥0.5h，过滤，滤液减压浓缩得到的固体用硅胶柱层析分离(洗脱剂为石油醚∶乙酸乙酯＝3∶1，v/v)，得产物S-取代-3-吲哚硫磷酸二乙酯2.80g，收率98％。1H NMR(500MHz,CDCl3)δ(ppm)9.83(s,1H),7.61(d,J＝7.7Hz,1H),7.16(d,J＝7.5Hz,1H),7.09～7.01(m,3H),4.16～4.07(m,4H),1.21(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)136.3(s),131.6(d,J＝6.1Hz),129.2(d,J＝1.8Hz),122.5(s),120.5(s),118.7(s),112.2(s),93.3(d,J＝7.3Hz),64.4(d,J＝6.6Hz),16.2(d,J＝7.1Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.8.HRMS Calcd forC12H16NNaO3PS+[M+Na]+308.0481,found 308.0478.
方法二：实施例2：S-取代-3-吲哚硫磷酸二乙酯的制备(化合物7)
在250mL双颈瓶中依次加入硫代磷酸二乙酯(1.70g,0.01mol)，加入乙腈10mL，在搅拌状态下加入过氧化叔丁醇(70％浓度，1.3g,0.01mol)，60℃保温反应8h，减压浓缩，然后用硅胶柱层析分离(洗脱剂为石油醚∶乙酸乙酯＝10∶1，v/v)，得产物过硫磷酰化合物3.21克，产率95％。31PNMR：21ppm。
在150mL反应瓶中，先依次加入吲哚(1.17g,10mmol)，过硫磷酰化合物(1.69g,5mol)，碘化钠(0.15g,1mmol)，加入乙腈20mL,再在搅拌状态下加入过氧化叔丁醇(70％浓度，2.6g,20mmol)，60℃保温反应8h。TLC检测反应已结束，停止反应。反应液冷却至室温，在搅拌下加入80mL乙酸乙酯，并用碳酸氢钠调pH为7～8；液体过滤后分液，有机相用15g无水硫酸钠干燥0.5h，过滤，滤液减压浓缩得到的固体用硅胶柱层析分离(洗脱剂为石油醚∶乙酸乙酯＝3∶1，v/v)，得产物S-取代-3-吲哚硫磷酸二乙酯2.6g，收率90％。
方法三：实施例3：S-取代-3-吲哚硫磷酸二乙酯的制备(化合物7)
在150mL反应瓶中，先依次加入氢亚磷酸二乙酯(2.07g,15mmol)，硫粉(0.48g,15mmol)，三乙胺(1.52g,15mmol)，碘化钠(0.15g,1mmol)，吲哚(1.17g,10mmol)，加入乙腈20mL,60℃保温反应20min，然后加入三氟乙酸，调至pH<3，加入过氧化叔丁醇(70％浓度，3.9g,30mmol)，80℃保温反应5h。TLC检测反应已结束，停止反应。反应液冷却至室温，在搅拌下加入80mL乙酸乙酯，并用碳酸氢钠调pH为7～8；液体过滤后分液，有机相用15g无水硫酸钠干燥0.5h，过滤，滤液减压浓缩得到的固体用硅胶柱层析分离(洗脱剂为石油醚∶乙酸乙酯＝3∶1，v/v)，得产物S-取代-3-吲哚硫磷酸二乙酯2.82g，收率80％。
实施例4：S-取代-3-(1-甲基)吲哚硫磷酸二乙酯的制备(化合物1)
利用方法一，以1-甲基吲哚为原料，收率92％。1H NMR(500MHz,CDCl3)δ(ppm)7.65(d,J＝7.9Hz,1H),7.25～7.12(m,4H),4.12～4.06(m,4H),3.72(s,3H),1.18(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)137.1(s),134.8(d,J＝5.43Hz),130.0(d,J＝2.5Hz),122.6(s),120.60(s),119.4(s),109.9(s),93.6(d,J＝7.7Hz),64.0(d,J＝6.3Hz),33.4(s),16.2(d,J＝7.2Hz).31P NMR(202MHz,CDCl3)δ(ppm)23.8.HRMS Calcd forC13H18NNaO3PS+[M+Na]+322.0637,found 322.0643.
实施例5：S-取代-3-(7-甲基)吲哚硫磷酸二乙酯的制备(化合物2)
利用方法一，以7-甲基吲哚为原料，用双氧水(30％浓度，2.0g,20mmol)取代TBHP，收率90％。1H NMR(500MHz,CDCl3)δ(ppm)9.72(s,1H),7.53(d,J＝7.9Hz,1H),7.19(dd,J＝4.2,3.2Hz,1H),7.08(dd,J＝7.5,8.7Hz,1H),6.9(d,J＝7.8Hz,1H),4.28～4.18(m,4H),2.20(s,3H),1.34(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)135.8(s),131.6(d,J＝6.0Hz),128.9(d,J＝1.8Hz),123.0(s),121.8(s),120.7(s),116.3(s),93.6(d,J＝7.3Hz),64.3(d,J＝6.6Hz),16.26(s),16.24(d,J＝6.8Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.9.HRMS Calcd for C13H18NNaO3PS+[M+Na]+322.0637,found 322.0637.
实施例6：S-取代-3-(2-甲基)吲哚硫磷酸二乙酯的制备(化合物3)
利用方法三，以2-甲基吲哚为原料，收率86％。1H NMR(500MHz,CDCl3)δ(ppm)9.57(s,1H),7.60(d,J＝7.8Hz,1H),7.17～7.05(m,3H),4.26～4.13(m,4H),2.22(d,J＝3.0Hz,3H),1.34(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)142.3(d,J＝6.3Hz),135.5(s),130.3(s),121.7(s),120.2(s),118.1(s),111.3(s),90.4(d,J＝6.9Hz),64.2(d,J＝7.1Hz),16.2(d,J＝7.1Hz),12,1(d,J＝1.7Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.7.HRMSCalcd for C13H18NNaO3PS+[M+Na]+322.0637,found 322.0637.
实施例7：S-取代-3-(5-甲氧羰基)吲哚硫磷酸二乙酯的制备(化合物4)
利用方法二，以5-甲氧羰基吲哚为原料，收率65％。1H NMR(500MHz,CDCl3)δ(ppm)10.49(s,1H),8.39(s,1H),7.68(d,J＝8.6Hz,1H),7.12～7.07(m,2H),4.32～4.18(m,4H),3.92(s,3H),1.35(t,J＝7.2Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)168.1(s),139.0(s),133.1(d,J＝6.3Hz),128.6(d,J＝1.6Hz),123.6(s),122.4,(s),121.6(s),112.0(s),94.8(d,J＝7.3Hz),64.7(d,J＝7.1Hz),51.9(s),16.1(d,J＝7.1Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.4.HRMS Calcd for C14H18NNaO5PS+[M+Na]+366.0536,found 366.0528.
实施例8：S-取代-3-(5-甲氧基)吲哚硫磷酸二乙酯的制备(化合物5)
利用方法一，以5-甲氧基吲哚为原料，用碘化钾取代碘化钠，收率81％。1H NMR(500MHz,CDCl3)δ(ppm)9.63(s,1H),7.26～7.10(m,3H),6.80-6.78(m,1H),4.26～4.14(m,4H),3.86(s,3H),1.30(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)155.0(s),131.9(d,J＝5.9Hz),131.3(s),129.9(d,J＝1.7Hz),113.05(s),112.97(s),100.4(s),93.1(d,J＝6.9Hz),64.3(d,J＝6.6Hz),55.9(s),16.2(d,J＝7.1Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.8.HRMS Calcd for C13H18NNaO4PS+[M+Na]+338.0586,found 338.0585.
实施例9：S-取代-3-(5-氯)吲哚硫磷酸二乙酯的制备(化合物6)
利用方法一，以5-氯吲哚为原料，用碘化钾取代碘化钠，收率89％。1H NMR(500MHz,CDCl3)δ(ppm)10.15(s,1H),7.59(s,1H),7.04～6.94(m,3H),4.33～4.20(m,4H),1.39(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)134.7(s),132.9(d,J＝5.8Hz),130.2(d,J＝1.6Hz),126.4(s),122.7(s),118.0(s),113.3(s),92.63(d,J＝6.9Hz),64.7(d,J＝7.0Hz),16.2(d,J＝7.1Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.8.HRMS Calcd forC12H15ClNNaO3PS+[M+Na]+342.0091,found342.0089.
实施例10：S-取代-3-(4-苯氧基)吲哚硫磷酸二乙酯的制备(化合物8)
利用方法三，以4-苯氧基吲哚为原料，用浓硫酸取代三氟乙酸，收率80％。1H NMR(500MHz,CDCl3)δ(ppm)9.94(s,1H),7.63(d,J＝7.6Hz,2H),7.40(dd,J＝7.9,7.5Hz,2H),7.32(dd,J＝8.1,7.3Hz,1H),7.12(s,1H),7.01(dd,J＝8.4,8.0Hz,1H),6.93(d,J＝8.3Hz,1H),6.59(d,J＝7.8Hz,1H),5.22(s,2H),4.19～4.04(m,4H),1.20(t,J＝7.1Hz,6H).13CNMR(125MHz,CDCl3)δ(ppm)153.0(s),138.3(s),137.6(s),131.2(d,J＝5.8Hz),128.5(s),127.7(s),127.3(s),123.1(s),118.6(d,J＝2.5Hz),106.0(s),102.2(s),92.6(s),70.2(s),64.1(d,J＝8.4Hz),16.1(d,J＝7.2Hz).31P NMR(202MHz,CDCl3)δ(ppm)25.3.HRMSCalcd for C19H22NNaO4PS+[M+Na]+414.0899,found 414.0892.
实施例11：S-取代-3-(5-溴)吲哚硫磷酸二乙酯的制备(化合物9)
利用方法一，以5-溴吲哚为原料，用乙醇作溶剂，收率85％。1H NMR(500MHz,CDCl3)δ(ppm)10.23(s,1H),7.74(s,1H),7.09～7.07(m,1H),7.01(dd,J＝4.2,3.4Hz,1H),6.9(d,J＝8.7Hz,1H),4.33～4.19(m,4H),1.39(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)135.0(s),132.8(d,J＝6.0Hz),130.7(d,J＝1.7Hz),125.2(s),121.0(s),113..98(s),113.69(s),92.4(d,J＝7.1Hz),64.7(d,J＝7.1Hz),16.2(d,J＝7.2Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.7.HRMS Calcd for C12H15BrNNaO3PS+[M+Na]+385.9586,found 385.9577.
实施例12：S-取代-3-(5-碘)吲哚硫磷酸二乙酯的制备(化合物10)
利用方法一，以5-碘吲哚为原料，用乙醇作溶剂，收率90％。1H NMR(500MHz,CDCl3)δ(ppm)10.25(s,1H),7.93(s,1H),7.24(d,J＝8.6Hz,1H),6.96(dd,J＝4.0,3.2Hz,1H),6.78(d,J＝8.6Hz,1H),4.33～4.20(m,4H),1.40(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)135.4(s),132.4(d,J＝6.2Hz),131.4(d,J＝1.6Hz),130.6(s),127.3(s),114.2(s),92.0(d,J＝7.2Hz),84.3(s),64.7(d,J＝7.1Hz),16.3(d,J＝7.2Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.7.HRMS Calcd for C12H15INNaO3PS+[M+Na]+433.9447,found 433.9440.
实施例13：S-取代-3-吲哚硫磷酸二甲酯的制备(化合物11)
利用方法一，以吲哚和氢亚磷酸二甲酯为原料，收率92％。1H NMR(500MHz,CDCl3)δ(ppm)9.55(s,1H),7.62(d,J＝7.6Hz,1H),7.18(d,J＝7.7Hz,1H),7.12～7.07(m,3H),3.76(d,J＝12.5Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)136.3(s),131.5(d,J＝6.0Hz),129.1(d,J＝1.7Hz,),122.7(s),120.8(s),118.6(s),112.2(s),93.2(d,J＝7.4Hz),54.6(d,J＝6.6Hz).31P NMR(202MHz,CDCl3)δ(ppm)27.7.HRMS Calcd for C10H12NNaO3PS+[M+Na]+280.0168,found 280.0162.
实施例14：S-取代-3-(2-苯基)吲哚硫磷酸二乙酯的制备(化合物12)
利用方法一，以2-苯基吲哚为原料，收率95％。1H NMR(500MHz,CDCl3)δ(ppm)10.14(s,1H),7.74(d,J＝7.5Hz,1H),7.28(d,J＝7.8Hz,1H),7.17～7.09(m,3H),4.83～4.76(m,2H),1.34(d,J＝6.3Hz,6H),1.26(d,J＝6.3Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)136.3(s),131.5(d,J＝6.0Hz),129.2(d,J＝2.0Hz,),122.3(s),120.3(s),119.1(s),112.2(s),93.8(d,J＝7.3Hz),73.5(d,J＝7.3Hz),24.0(d,J＝4.4Hz),23.7(d,J＝5.4Hz).31P NMR(202MHz,CDCl3)δ(ppm)22.9.HRMS Calcd for C14H20NNaO3PS+[M+Na]+336.0794,found336.0794.
实施例14：S-取代-3-(1-甲基-5-羧基)吲哚硫磷酸二乙酯的制备(化合物15)
利用方法一，以1-甲基-5-羧基吲哚为原料，收率65％。1H NMR(500MHz,CDCl3)δ(ppm)8.56(s,1H),8.03(d,J＝8.7Hz,1H),7.37(d,J＝3.6Hz,1H),7.33(d,J＝8.7Hz,1H),4.26～4.13(m,4H),3.82(s,3H),1.27(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)172.4(s),139.9(s),136.4(d,J＝5.6Hz),129.5(d,J＝1.9Hz),124.5(s),123.2(s),122.3(s),109.8(s),96.0(d,J＝7.6Hz),,64.4(d,J＝6.5Hz),33.6(s),16.2(d,J＝6.9Hz).31PNMR(202MHz,CDCl3)δ(ppm)23.3.HRMS Calcd for C14H18NNaO5PS+[M+Na]+366.0536,found366.0530.
实施例15：S-取代-3-(1-苯基)吲哚硫磷酸二乙酯的制备(化合物16)
利用方法一，以1-苯基吲哚为原料，收率91％。1H NMR(500MHz,CDCl3)δ(ppm)7.82～7.79(m,1H),7.55-7.46(m,6H),7.38(dd,J＝7.6,7.2Hz,1H),7.28～7.23(m,2H),4.27～4.14(m,4H),1.27(t,J＝7.2Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)138.8(s),136.3(s),133.6(d,J＝6.1Hz),130.4(d,J＝2.0Hz),129.8(s),127.3(s),124.5(s),123.4(s),121.4(s),119.7(s),111.0(s),97.1(d,J＝7.5Hz),64.1(d,J＝6.3Hz),16.1(d,J＝6.9Hz).31PNMR(202MHz,CDCl3)δ(ppm)23.4.HRMS Calcd for C18H20NNaO3PS+[M+Na]+384.0794,found384.0789.
实施例16：S-取代-3-(5-氟)吲哚硫磷酸二乙酯的制备(化合物18)
利用方法三，以5-氟吲哚为原料，收率80％。1H NMR(500MHz,CDCl3)δ(ppm)10.06(s,1H),7.21～7.18(m,1H),7.01～6.93(m,2H),6.72～6.68(m,1H),4.22～4.10(m,4H),1.28(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)158.6(d,J＝235.6Hz),133.3(d,J＝5.7Hz),132.8(s),129.7(d,J＝10.1Hz),113.0(d,J＝9.7Hz),110.9(d,J＝26.4Hz),103.5(d,J＝24.5Hz),92.9(s),64.6(d,J＝6.9Hz),16.2(d,J＝7.1Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.8.HRMS Calcd for C12H15FNNaO3PS+[M+Na]+326.0386,found 326.0381.
实施例17：S-取代-3-(5-甲酰基)吲哚硫磷酸二乙酯的制备(化合物19)
利用方法一，以5-甲酰基吲哚为原料，收率60％。1H NMR(500MHz,CDCl3)δ(ppm)10.56(s,1H),10.01(S,1H),8.18(s,1H),7.49(d,J＝8.4Hz,1H),7.16(dd,J＝4.3,2.9Hz,1H),7.09(d,J＝8.5Hz,1H),4.36～4.23(m,4H),1.39(t,J＝7.0Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)192.4(s),139.9(s),133.5(d,J＝6.3Hz),130.0(s),128.9(d,J＝1.7Hz),123.08(s),122.99(s),112.7(s),95.5(d,J＝7.2Hz),64.7(d,J＝7.1Hz),16.1(d,J＝7.0Hz).31P NMR(202MHz,CDCl3)δ(ppm)24.4.HRMS Calcd for C13H16NNaO4PS+[M+Na]+336.0430,found 336.0430.
实施例18：S-取代-3-(1-(3’-溴)丙基)吲哚硫磷酸二乙酯的制备(化合物22)
利用方法一，以1-(3’-溴)丙基吲哚为原料，收率70％。1H NMR(500MHz,CDCl3)δ(ppm)7.66(d,J＝7.8Hz,1H),7.31～7.29(m,2H),7.20～7.12(m,2H),4.07(t,J＝8.0Hz,2H),4.14～4.05(m,4H),3,21(t,J＝6.0Hz,2H),2.28～2.23(m,2H)1.18(t,J＝7.0Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)136.2(s),133.9(d,J＝5.7Hz),130.1(d,J＝2.0Hz),122.8(s),120.8(s),119.7(s),109.9(s),94.5(d,J＝7.4Hz),64.0(d,J＝6.3Hz),44.4(s),32.5(s),30.2(s),16.2(d,J＝7.1Hz).31P NMR(202MHz,CDCl3)δ(ppm)23.6.HRMS Calcd forC15H21BrNNaO3PS+[M+Na]+428.0055,found 428.0047.
实施例19：S-取代-3-(2-p-甲氧基苯基)咪唑并[1,2-a]吡啶硫磷酸二乙酯的制备(化合物26)
方法五：在150mL反应瓶中，先依次加入2-p-甲氧基苯基咪唑并[1,2-a]吡啶(2.24g,10mmol)，硫代磷酸二乙酯(2.55g,15mmol)，碘化钾(0.17g,1mmol)，加入乙腈20mL,再在搅拌状态下加入过氧化叔丁醇(70％浓度，2.6g,20mmol)，60℃保温反应2h。TLC检测反应已结束，停止反应。反应液冷却至室温，在搅拌下加入80mL乙酸乙酯，并用碳酸氢钠调pH为7～8；液体过滤后分液，有机相用15g无水硫酸钠干燥0.5h，过滤，滤液减压浓缩得到的固体用硅胶柱层析分离(洗脱剂为石油醚∶乙酸乙酯＝3∶1,v/v)，得产物S-取代-3-(2-p-甲氧基苯基)咪唑并[1,2-a]吡啶硫磷酸二乙酯3.32g，收率85％。1H NMR(500MHz,CDCl3)δ(ppm)8.49(d,J＝6.8Hz,1H),8.14(d,J＝8.8Hz,2H),7.62(d,J＝8.9Hz,1H),7.29(dd,J＝9.3,8.5Hz,1H),6.99(d,J＝8.8Hz,2H),6.91(dd,J＝7.5,6.8Hz,1H),3.98～3.84(m,4H),3.83(s,3H),1.03(t,J＝7.0Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)160.0(s),151.1(d,J＝5.6Hz),147.2(s),130.0(s),126.5(s),126.0(d,J＝1.8Hz),125.3(s),117.3(s),113.8(s),112.6(s),99.0(d,J＝7.8Hz),64.7(d,J＝7.2Hz),55.4(s),15.9(d,J＝7.0Hz).31PNMR(202MHz,CDCl3)δ(ppm)19.2.HRMS Calcd for C18H21N2NaO4PS+[M+Na]+415.0852,found415.0846.
实施例20：S-取代-3-(4-甲基-2-苯基)咪唑并[1,2-a]吡啶硫磷酸二乙酯的制备(化合物28)
利用方法五，以4-甲基-2-苯基咪唑并[1,2-a]吡啶为原料，收率83％。1H NMR(500MHz,CDCl3)δ(ppm)8.39(d,J＝6.8Hz,1H),8.14(d,J＝7.7Hz,2H),7.46(dd,J＝8.6,7.7Hz,2H),7.37(dd,J＝8.4,7.4Hz,1H),7.10(d,J＝6.8Hz,1H),6.85(dd,J＝7.4,6.8Hz,1H),3.94～3.78(m,4H),2.65(s,3H),1.01(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)150.9(d,J＝5.6Hz),147.6(s),133.6(d,J＝1.9Hz),128.9(s),128.5(s),128.4(s),127.6(s),125.4(s),123.2(s),112.8(s),100.3(d,J＝8.0Hz),64.7(d,J＝6.9Hz),16.8(s),15.9(d,J＝6.8Hz).31P NMR(202MHz,CDCl3)δ(ppm)19.2.HRMS Calcd forC18H21N2NaO3PS+[M+Na]+399.0903,found 399.0909.
实施例21：S-取代-3-(2-p-氯苯基)咪唑并[1,2-a]吡啶硫磷酸二乙酯的制备(化合物31)
利用方法五，以2-p-氯苯基咪唑并[1,2-a]吡啶为原料，收率83％。1H NMR(500MHz,CDCl3)δ(ppm)8.52(d,J＝6.9Hz,1H),8.15(d,J＝8.4Hz,2H),7.65(d,J＝9.0Hz,1H),7.44(dd,J＝8.6,8.4Hz,2H),7.33(dd,J＝8.1.7.8Hz,1H),6.96(dd,J＝7.4,6.8Hz,1H),4.02～3.85(m,4H),1.06(t,J＝7.1Hz,6H).13C NMR(125MHz,CDCl3)δ(ppm)149.9(d,J＝5.6Hz),147.2(d,J＝2.2Hz),134.6(s),131.9(s),129.9(s),128.6(s),126.9(s),125.4(s),117.6(s),112.9(s),100.1(d,J＝7.9Hz),64.9(d,J＝7.4Hz),15.9(d,J＝6.8Hz).31PNMR(202MHz,CDCl3)δ(ppm)19.0.HRMS Calcd for C17H18ClN2NaO3PS+[M+Na]+419.0356,found 419.0354.
实施例22：S-取代-3-(2-苯基)咪唑并[1,2-a]吡啶硫磷酸二异丙酯的制备(化合物32)
利用方法五，以2-苯基咪唑并[1,2-a]吡啶和亚磷酸二异丙酯为原料，收率90％。1HNMR(500MHz,CDCl3)δ(ppm)8.56(d,J＝6.9Hz,1H),8.20(d,J＝7.84Hz,2H),7.64(d,J＝9.0Hz,1H),7.45(dd,J＝8.1,7.7Hz,2H),7.37(dd,J＝8.2,7.4Hz,1H),7.31(dd,J＝9.1,7.5Hz,1H),6.93(dd,J＝7.5,6.8Hz,1H),4.63～4.56(m,2H),1.13～1.04(m,12H).13C NMR(125MHz,CDCl3)δ(ppm)151.0(d,J＝5.8Hz),147.2(d,J＝1.8Hz),133.5(d,J＝2.4Hz),128.9(s),128.6(s),128.4(s),126.6(s),125.8(s),117.5(s),112.6(s),100.7(d,J＝8.0Hz),74.5(d,J＝8.1Hz),23.7(d,J＝4.2Hz),23.4(d,J＝5.5Hz).31P NMR(202MHz,CDCl3)δ(ppm)17.4.HRMS Calcd for C19H23N2NaO3PS+[M+Na]+413.1059,found 413.1058.
实施例23：S-取代-3-(4,6-二甲基-2-苯基)咪唑并[1,2-a]吡啶硫磷酸二乙酯的制备(化合物33)
利用方法五，以4,6-二甲基-2-苯基咪唑并[1,2-a]吡啶为原料，收率80％。1H NMR(500MHz,CDCl3)δ(ppm)8.01(d,J＝7.7Hz,2H),7.46(dd,J＝8.2,7.6Hz,2H),7.38(dd,J＝8.5,7.5Hz,1H),7.34(s,1H),6.47(s,1H),3.93～3.51(m,4H),3.13(s,3H),2.37(s,3H),1.01～0.87(m,6H).13C NMR(125MHz,CDCl3)δ(ppm)153.7(d,J＝5.7Hz),149.3(d,J＝2.2Hz),138.04(s),137.97(s),133.8(s),129.6(s),128.4(s),128.2(s),117.8(s),114.8(s),99.8(d,J＝9.2Hz),64.4(d,J＝68.6Hz),21.9(s),21.0(s),15.8(d,J＝6.3Hz).31PNMR(202MHz,CDCl3)δ(ppm)19.1.HRMS Calcd for C19H23N2NaO3PS+[M+Na]+413.1059,found413.1059.
实施例24：体外生物活性评价——抗炎活性评价
炎症是一种非常常见且重要的基本病理过程，它与许多疾病相关，如癌症、动脉粥样硬化、糖尿病和阿尔茨海默病。促炎细胞因子如肿瘤坏死因子(TNF-)，白细胞介素1(IL-1)和白细胞介素-6(IL-6)在炎症过程中起着重要作用。利用实时荧光定量PCR法，评估合成化合物在脂多糖(LPS)刺激的巨噬细胞Raw 264.7炎症模型中的抗炎特性。
实验方法：巨噬细胞Raw 264.7用含20％血清的RPMI-1640，37℃，5％CO2培养。将Raw 264.7接种于6孔板中，每孔6×105个细胞，培养12h后换无血清培养基饥饿细胞，6h后先加入一定浓度的化合物预处理2h。而后加入LPS(工作浓度100ng/mL)，诱导3h后移去培养基，用PBS洗2-3次。用TRIZOL(Yesen,Shanghai,China)提取总RNA；再利用逆转录试剂盒(HifairTM first Strand cDNA Synthesis Kit,Yesen,Shanghai,China)将提取出的RNA进行逆转录得到cDNA；最后用
Green(Yesen,Shanghai,China)将获得的cDNA进行实时定量荧光PCR检测IL-6，IL-1β，TNF-α相对于各自GAPDH的mRNA表达水平。
实验结果：发现S-取代-3-吲哚硫磷酸酯类衍生物具有一定的抗炎活性(如表1所示)；其中4、5、16、26、33抗炎效果较好，对LPS诱导的TNF-、IL-1、IL-6三个因子中的1个或2个因子的半数抑制率浓度(IC50)在0.5～10μmol/L的范围内。
表1、部分活性化合物的抗炎作用(50μmol/L)
*表示IC50在0.5～10μmol/L范围内。
实施例25：体外生物活性评价——细胞毒性评价
实验方法：MTT法。巨噬细胞Raw 264.7用含20％血清的RPMI-1640，37℃，5％CO2培养。
将Raw 264.7接种于96孔板中，每孔5×103个细胞，培养过夜后用含0.5％血清的培养基加测试化合物，使其终浓度为20μmol/L。培养24h后加入MTT(终浓度为0.5mg/mL)，37℃，5％CO2培养3-4h后，移去培养基，每孔加入100μL DMSO，560nm波长下测吸光值。
实验结果：利用MTT法测定化合物的细胞毒性(如图1所示)，发现化合物7、20、33有一定的细胞毒性，而1、4、5、16、18、19、22等的细胞毒性低。
Claims (3)
1.S-取代-3-吲哚硫磷酸酯类衍生物，其特征在于选自以下结构式的化合物：
2.包含如权利要求1所述S-取代-3-吲哚硫磷酸酯类衍生物的药物组合物。
3.如权利要求1所述S-取代-3-吲哚硫磷酸酯类衍生物或权利要求2所述S-取代-3-吲哚硫磷酸酯类衍生物的药物组合物在制备诊断和治疗炎症性药物的应用，所述炎症选自胃炎、肺炎。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910205589.1A CN109970794B (zh) | 2019-03-19 | 2019-03-19 | S-取代-3-吲哚硫磷酸酯类衍生物及制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910205589.1A CN109970794B (zh) | 2019-03-19 | 2019-03-19 | S-取代-3-吲哚硫磷酸酯类衍生物及制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109970794A CN109970794A (zh) | 2019-07-05 |
| CN109970794B true CN109970794B (zh) | 2020-07-03 |
Family
ID=67079394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910205589.1A Expired - Fee Related CN109970794B (zh) | 2019-03-19 | 2019-03-19 | S-取代-3-吲哚硫磷酸酯类衍生物及制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109970794B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111662322A (zh) * | 2020-07-20 | 2020-09-15 | 温州大学 | 一种硫代有机膦酸衍生物的高效绿色制备方法 |
-
2019
- 2019-03-19 CN CN201910205589.1A patent/CN109970794B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN109970794A (zh) | 2019-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009112678A2 (fr) | Derives de carboxam i d es azabicycliques, leur preparation et leur application en therapeutique. | |
| KR101064092B1 (ko) | 미엘로퍼옥시다제 억제제로서의 티오크산틴 유도체 | |
| Davidsen et al. | N-(Acyloxyalkyl) pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist | |
| ES2275021T3 (es) | Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico. | |
| JP4938012B2 (ja) | Ｎ（アリールアルキル）−１ｈ−ピロロピリジン−２−カルボキサミド誘導体、その調製およびその治療目的使用 | |
| WO2014104757A1 (ko) | Btk 키나아제 억제제로서의 2,3-디하이드로-이소인돌-1-온 유도체 및 이를 함유하는 약학적 조성물 | |
| FR2864084A1 (fr) | Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments | |
| CN109134463B (zh) | β-咔啉类5型磷酸二酯酶抑制剂及其制备方法和用途 | |
| KR20070094833A (ko) | Ｎ-(헤테로아릴)-１ｈ-인돌-2-카르복스아미드 유도체 및바닐로이드 ｔｒｐｖ１ 수용체 리간드로서의 그의 용도 | |
| CN109970794B (zh) | S-取代-3-吲哚硫磷酸酯类衍生物及制备方法和应用 | |
| WO2023005267A1 (zh) | 一种苯并[b]硒吩类STING调控剂、其制备方法及用途 | |
| JPH11504913A (ja) | アザシクロアルカン誘導体、その製造および治療への適用 | |
| CN113387957B (zh) | 螺环吲哚酮-吡咯烷碳酸酯化合物和其组合物、制备方法及用途 | |
| Soltanzadeh et al. | Unexpected formation of 5-alkylidene derivatives of hydantoin from the Michael addition of 4-phenylurazole to fumaric esters | |
| CN107235992A (zh) | 吲哚酮螺四氢噻吩类化合物及其盐、制备方法和应用 | |
| CN108864089B (zh) | 一种吲哚并吡啶酮药物分子及其制备方法和应用 | |
| CN108997319B (zh) | 硫代咪唑烷酮衍生物及其合成方法与应用 | |
| AP118A (en) | Prodrugs of antiflammatory 3-acyl-2-oxindole-1-carboxamides | |
| CN102137842A (zh) | 3-吡咯取代的2-吲哚酮衍生物的制备 | |
| CN110357892B (zh) | 四氢嘧啶并[1,2-a]吲哚衍生物及其合成方法与应用 | |
| JP2008528667A (ja) | 化合物 | |
| CN105503866A (zh) | 酰化物中间体及其合成方法和在制备他达拉非方面的应用 | |
| CN113087668B (zh) | 一类苯并咪唑二聚体、其制备方法及用途 | |
| CN115010715B (zh) | 3-(吲哚-2-基)琥珀酰亚胺和吲哚并苯并二氮卓类化合物的合成方法及抗癌活性 | |
| CN115108970B (zh) | 二酰胺类衍生物及其制药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200703 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |